Advertisement

Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois

  • Dylan L. SteenEmail author
Review Article
  • 19 Downloads

After another exciting conference, this article highlights some of the many studies presented. We encourage readers to explore the broader content of the AHA presentations for other interesting studies.

Eicosapentaenoic acid (EPA) preparation demonstrates cardiovascular outcomes benefit

In patients treated with standard of care therapies (e.g. statins), risk for atherothrombotic events remains high. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) studied the efficacy and safety of a purified and stable EPA preparation for the reduction of cardiovascular (CV) events in high risk patients with controlled low-density lipoprotein cholesterol (LDL-C) but elevated triglycerdies [1]. Key eligibility criteria were: (1) age ≥ 45 years with established CV disease or age ≥ 50 years with diabetes mellitus and at least one additional risk factor; (2) fasting triglyceride level of 150–499 mg/dL; and (3) fasting LDL-C of 41–100 mg/dL on a stable dose of...

Keywords

Conference Highlights Trials Review 

Notes

References

  1. 1.
    Bhatt DL, Steg PG, Miller M et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. NEJM 380(1):11–22CrossRefPubMedGoogle Scholar
  2. 2.
    Kastelein JJP, Stroes ESG (2019) FISHing for the miracle of eicosapentaenoic acid. NEJM 380(1):89–90CrossRefPubMedGoogle Scholar
  3. 3.
    Wiviott SD, Raz I, Bonaca MP et al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. NEJM.  https://doi.org/10.1056/NEJMoa1812389 Google Scholar
  4. 4.
    Zelniker TA, Wiviott SD, Raz I et al (2018) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet.  https://doi.org/10.1016/S0140-6736(18)32590-X PubMedGoogle Scholar
  5. 5.
    Velazquez EJ, Morrow DA, DeVore AD et al (2018) Angiotensin-neprilysin inhibition in acute decompensated heart failure. NEJM.  https://doi.org/10.1056/NEJMoa1812851 PubMedGoogle Scholar
  6. 6.
    Zenati MA, Bhatt DL, Bakaeen FG et al (2018) Randomized trial of endoscopic or open vein-graft harvesting for coronary-artery bypass. NEJM.  https://doi.org/10.1056/NEJMoa1812390 Google Scholar
  7. 7.
    Grundy SM, Stone NJ, Bailey AL et al (2018) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circ.  https://doi.org/10.1161/CIR.0000000000000625 Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.University of CincinnatiCincinnatiUSA

Personalised recommendations